致力于肺癌的基础与临床研究多年，主持多个国家与市级科研项目，已发表相关SCI30余篇，获得专利多项。专注于中晚期非小细胞肺癌个体化精准分析及治疗，带领研究团队积极开展肺癌的液态活检研究及大数据分析，收集临床标本开展科学研究；同时，积极开展肺癌靶向治疗的耐药研究及纳米主动靶向化疗研究。
（一）发表论文：
1、通讯作者：Competitive evolution of NSCLC tumor clones and the drug resistance
mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Heliyon,
2018.
2、通讯作者：Engineering docetaxel-loaded micelles for nonsmall cell lung cancer:
a comparative study of microfluidic and bulk nanoparticle preparation. RSC Advances, 2018.
3、并列通讯作者：The Evolution and Expression Pattern of Human Overlapping LncRNA and
Protein-coding Gene Pairs. Scientific
Reports,2017.
4、通讯作者：SPOP promotes SIRT2 degradation and suppresses non-small cell lung
cancer cell growth. Biochem Biophys Res
Commun，2017.
5、并列通讯作者：Cancer-related triplets of mRNA-lncRNA-miRNA revealed by integrative
network in uterine corpus endometrial carcinoma.
BioMed Research International, 2017.
（二）科研课题
张江高科技园区重点项目子课题（在研，第一负责人）；项目名称：建立NGS技术检测外周血cfDNA的检测平台（2016-08）；研究经费：800万；研究时间：2016年8月至2020年12月。
中央高校基本科研业务费专项资金资助（已结题，第一负责人）；项目名称：c-KIT/PDGFα-EMT-肿瘤亚克隆演化在非小细胞肺癌EGFR-TKIs获得性耐药中作用及分子机制探讨（22120180369）；研究经费：5万；研究时间：2018年9月至2019年8月。
国基金青年项目（已结题，第一负责人）；项目名称：国基金青年项目（已结题，第一负责人）；项目名称：分化抑制因子ID1在非小细胞肺癌EGFR-TKIs耐药中的作用和机制研究”（项目批准号：81301994）研究经费：23万；研究时间：2014年1月至2016年12月。
（三）专利：
1、获得软件著作权1项：
上海市肺科医院病历随访系统V1.0（2016年10月29日），2017SR419017
2、获得实用新型专利：
穿刺固定器（2018年1月26日）；ZL201621310554.2
3、发明专利3项（公布阶段）：
（1）一种人表皮生长因子酪氨酸激酶抑制剂获得性耐药肺癌细胞系及其建立方法；2018107760600；第一发明人。
（2）一种基于微流控技术控制纳米颗粒质量参数的方法；2016103921341；第一发明人。
（3）一种用于医学辅助教学的疾病知识管理系统及操作方法；201610015215X；第三发明人。
（四）举办会议：
2019年12月，承办
全国肺癌个体化精准治疗新进展研讨会（I类继续教育学分10分，项目编号：2019-03-02-006，沪）
Committed
to basic and clinical research of lung cancer for many years, have been presided
over many national and municipal scientific research projects, published a number of
papers of SCI, obtained patents for invention. Having been devoted to the research on drug resistance
in targeted therapy for lung cancer, my team also did basic research on liquid
biopsy for advanced lung cancer and carried out big clinical data analysis, stored
a large number of clinical tissues for basic research. We also focus on nano-targeted
chemotherapy of lung cancer.
1.Published Articles
(1)
Corresponding author: Competitive evolution of NSCLC tumor clones and the drug
resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Heliyon,
2018.
(2)
Corresponding author: Engineering docetaxel-loaded micelles for non-small cell
lung cancer: a comparative study of microfluidic and bulk nanoparticle
preparation.2018.
(3)
Corresponding author: The Evolution and Expression Pattern of Human Overlapping
LncRNA and Protein-coding Gene Pairs. Scientific Reports, 2017.
(4)
Corresponding author: SPOP promotes SIRT2 degradation and suppresses non-small
cell lung cancer cell growth. Biochem Biophys Res Commun，2017.
(5)
Corresponding author: Cancer-related triplets of mRNA-lncRNA-miRNA revealed by
integrative network in uterine corpus endometrial carcinoma. BioMed Research
International, 2017.
2.Research project
(1)Sub-Project
of Foundation in Zhangjiang High-tech Park (In progress, the chief person in
charge): Establishment of a platform for detecting cfDNA in peripheral blood by
NGS. Funds: 8million; Time: 2016/8-2020/12.
(2)Fundamental
Research Funds for the Central Universities (completed, the chief person in
charge): Role and mechanism of c-KIT/PDGF alpha-EMT Tumor Subclone Evolution in
Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer(Approval Number:
22120180369); Funds: 50 thousand; Time: 2018/9-2019/8.
(3)National
Natural Science Foundation Youth Project (completed, the chief person in charge):
Role and mechanism of differentiation inhibitor ID1 in EGFR-TKIs resistance in
non-small cell lung cancer (Approval Number: 81301994). Funds: 230 thousand;
Time: 2014/1-2016/12.
3.Patents:
(1)Software
copyright:
Medical
Record Follow-up System of Shanghai Pulmonary Hospital V1.0(2016/10/29) 2017SR419017
(2)Utility
model patent:
Pulmonary
puncture fixator (2018/1/26)
ZL201621310554.2
(3)
Invention patents (Announcement):
①Establishment
of a human lung cancer cell line with acquired resistant to epidermal growth
factor tyrosine kinase inhibitor; 2018107760600; First inventor.
②A Method
of Controlling the Quality Parameters of Nanoparticles Based on Microfluidic
Technology; 2016103921341; First inventor.
③A Kind
of Disease Knowledge Management System and Its Operating Method for Medical
Assistant Teaching; 201610015215X; Third Inventor.
4.Academic Conferences
In
December 2019, we undertook the national seminars on advances in individualized
precision treatment of lung cancer (Class I continuing education credit 10, No:
2019-03-02-006,
Shanghai).
